title: A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
abstract: OBJECTIVE
  The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix.
  
  
  METHODS
  PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m(2) was given to the first 11 patients and was reduced to 560 mg/m(2) for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients.
  
  
  RESULTS
  Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia.
  
  
  CONCLUSIONS
  PZA at the dose and schedule employed, has insignificant activity in this population.
authors.affiliation: Department of Reproductive Medicine, Medical Center, University of California, San Diego, 402 Dickinson Street, San Diego, CA 92103-8433, USA.
authors.forename: Steven C
authors.initials: SC
authors.lastname: Plaxe
authors.forename: John A
authors.initials: JA
authors.lastname: Blessing
authors.forename: George
authors.initials: G
authors.lastname: Olt
authors.forename: Nader
authors.initials: N
authors.lastname: Husseinzadah
authors.forename: Samuel S
authors.initials: SS
authors.lastname: Lentz
authors.forename: Koen
authors.initials: K
authors.lastname: DeGeest
authors.forename: Fidel A
authors.initials: FA
authors.lastname: Valea
mesh_terms: D000166:Acridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007364:Intercalating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D016879:Salvage Therapy; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000166:Acridines; D004791:Enzyme Inhibitors; D007364:Intercalating Agents; D019384:Nucleic Acid Synthesis Inhibitors; D011720:Pyrazoles; C064541:NSC 366140